Stock comparison
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BRKRP
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Market cap
$53.05B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BRKRP | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 77B | LMAT |
| Benjamin Graham | 45D | 89A | LMAT |
| Philip Fisher |
Side-by-side metrics
| Metric | BRKRP | LMAT |
|---|---|---|
| Market cap | $53.05B | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 59.6x | 36.6x |
| ROIC (TTM) | -2.92% | 9.43% |
| Gross margin | 45.56% | 72.39% |
| Net margin | -0.34% | 24.35% |
| Revenue CAGR 5y | 9.19% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BRKRP leads on
- P/E (TTM)-vs 37.1x+106%
- Market cap$53.05Bvs $2.23B+96%
LMAT leads on
- ROIC (TTM)9.43%vs -2.92%+131%
More like LMAT
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.